



May 13, 2025

Consolidated Financial Results for the Year Ended March 31, 2025

[Japanese GAAP]

Company name: ROHTO PHARMACEUTICAL CO.,LTD.

Listing: Tokyo Stock Exchange

Securities code: 4527

URL: <https://www.rohto.co.jp/>

Representative: Masashi Sugimoto

President and COO

Inquiries: Masaya Saito

Vice President and CFO

Telephone: +81-6-6758-8223

Scheduled date of annual general meeting of shareholders: June 26, 2025

Scheduled date to commence dividend payments: June 12, 2025

Scheduled date to file annual securities report: June 25, 2025

Preparation of supplementary material on financial results: Yes

Holding of financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (April 1, 2024 to March 31, 2025)

(1) Consolidated Operating Results

(Percentages indicate year-on-year changes.)

	Net sales		Operating income		Ordinary income		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year ended March 31, 2025	308,625	14.0	38,939	(2.8)	40,430	(4.7)	31,006	0.2
March 31, 2024	270,840	13.5	40,048	17.9	42,434	19.3	30,936	17.3

(Note) Comprehensive income: Fiscal year ended March 31, 2025: ¥ 35,012 million [(19.8)%]

Fiscal year ended March 31, 2024: ¥ 43,647 million [19.4%]

	Net income per share	Diluted net income per share	Rate of return on equity	Ordinary income to total assets ratio	Operating income to net sales ratio
	Yen	Yen	%	%	%
Fiscal year ended March 31, 2025	136.11	135.44	12.3	10.5	12.6
March 31, 2024	135.61	135.21	13.6	12.9	14.8

(Reference) Equity in earnings (losses) of affiliated companies: Fiscal year ended March 31, 2025: ¥ 166 million

Fiscal year ended March 31, 2024: ¥ (289) million

(2) Consolidated Financial Position

	Total assets	Net assets	Capital adequacy ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
As of March 31, 2025	421,875	271,440	61.6	1,149.35
March 31, 2024	346,175	247,036	71.0	1,078.04

(Reference) Equity: As of March 31, 2025: ¥ 259,712 million

As of March 31, 2024: ¥ 245,942 million

(3) Consolidated Cash Flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at the end of period
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Fiscal year ended March 31, 2025	36,917	(89,170)	35,319	73,221
March 31, 2024	34,245	(16,317)	(13,784)	86,562

2. Dividends

	Annual dividends					Total dividends	Payout ratio (consolidated)	Dividends to net assets (consolidated)
	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total			
Fiscal year ended	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
March 31, 2024	-	12.00	-	15.00	27.00	6,159	19.9	2.7
March 31, 2025	-	16.00	-	20.00	36.00	8,169	26.4	3.2
Fiscal year ending March 31, 2026 (Forecast)	-	21.00	-	21.00	42.00		30.5	

3. Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2026 (April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating income		Ordinary income		Profit attributable to owners of parent		Net income per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	334,500	8.4	39,000	0.2	40,500	0.2	31,100	0.3	137.63

(Note) From the viewpoint of promoting constructive dialogue for medium-to long-term corporate value enhancement, we will disclose the earnings forecast for the full year only

* Notes:

(1) Significant changes in the scope of consolidation during the period:

Yes

Newly included: 46 (Company name: Soar R2M Pte. Ltd., Rohto-Mentholatum Austria GmbH, Eu Yan Sang International Ltd., and 43 others)

Excluded: 3 (Company name: Mentholatum Shanghai Cosmetics Company Ltd. and 2 others)

(Note) For details, please refer “(5) Notes to Consolidated Financial Statements”, under “3. Consolidated Financial Statements and Major Notes” on page 18 of the attachment.

(2) Changes in accounting policies, changes in accounting estimates, and restatement

1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes

2) Changes in accounting policies due to other reasons: None

3) Changes in accounting estimates: None

4) Restatement: None

(Note) For details, please refer “(5) Notes to Consolidated Financial Statements”, under “3. Consolidated Financial Statements and Major Notes” on page 18 of the attachment.

(3) Number of issued shares (common shares)

1) Total number of issued shares at the end of the period (including treasury shares):

March 31, 2025: 236,178,310 shares

March 31, 2024: 236,178,310 shares

2) Number of treasury shares at the end of the period:

March 31, 2025: 10,213,934 shares

March 31, 2024: 8,039,532 shares

3) Average number of shares outstanding during the period:

Fiscal Year ended March 31, 2025: 227,804,227 shares

Fiscal Year ended March 31, 2024: 228,138,880 shares

(Reference) Overview of Non-consolidated Financial Results

1. Non-consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (April 1, 2024 to March 31, 2025)

(1) Non-consolidated Operating Results

(Percentages indicate year-on-year changes.)

	Net sales		Operating income		Ordinary income		Net income	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
March 31, 2025	136,557	5.9	20,026	(6.6)	22,679	(15.0)	18,860	(5.6)
March 31, 2024	128,937	11.8	21,434	15.2	26,696	18.9	19,970	20.5

	Net income per share	Diluted net income per share
Fiscal year ended	Yen	Yen
March 31, 2025	82.79	82.38
March 31, 2024	87.54	87.28

(2) Non-consolidated Financial Position

	Total assets	Net assets	Capital adequacy ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
March 31, 2025	232,738	159,288	68.3	703.23
March 31, 2024	208,563	154,272	73.8	674.54

(Reference) Equity: As of March 31, 2025: ¥ 158,905 million

As of March 31, 2024: ¥ 153,889 million

(Note) Differences between the results for the current fiscal year and the results for the previous fiscal year occurred in capital adequacy ratio mainly owing to the issuance of convertible-bond-type bonds with share acquisition rights and the purchase of treasury shares in the current fiscal year.

Note 1: This summary report is not subject to the audit conducted by certified public accountants or audit firms.

Note 2: Cautionary statement with respect to forward-looking statements and other special items Forecasts regarding future performance in these materials are based on assumptions judged to be valid and information available to the Company at the time the materials were created. These materials are not promises by the Company regarding future performance. Actual results of operations may differ significantly from the forecasts depending on various factors. For discussion of the assumptions and other factors considered by the Company in preparing the above projections, please refer to page 5 of the attachments “1. Overview of Results of Operations and Other Information, (4) Future Outlook.

Contents of Attachments

1. Overview of Results of Operations and Other Information	2
(1) Explanation of Results of Operations	2
(2) Overview of Financial Position	3
(3) Overview of Cash Flows	4
(4) Future Outlook	5
2. Basic Approach to the Selection of Accounting Standards	6
3. Consolidated Financial Statements and Major Notes	7
(1) Consolidated Balance Sheets	7
(2) Consolidated Statements of Income and Comprehensive Income	9
(3) Consolidated Statements of Change in Shareholders' Equity	12
(4) Consolidated Statements of Cash Flows	16
(5) Notes to Consolidated Financial Statements	18
Going Concern Assumption	18
Changes in Accounting Policies	18
Changes in Presentation	18
Changes in the Scope of Consolidation and the Scope of Application of Equity Method	19
Business Combinations	20
Segment and Other Information	24
Per-share Information	28
Material Subsequent Events	28

1. Overview of Results of Operations and Other Information

(1) Explanation of Results of Operations

(Millions of yen)

	Net sales	Operating income	Ordinary income	Profit attributable to owners of parent
Fiscal year ended Mar. 31, 2025	308,625	38,939	40,430	31,006
Fiscal year ended Mar. 31, 2024	270,840	40,048	42,434	30,936
Year-on-year change (%)	14.0	(2.8)	(4.7)	0.2

During the current fiscal year, the Japanese economy showed a moderate recovery owing to improvements in the employment and income environment, as well as an increase in the number of foreign visitors to Japan against the backdrop of the weak yen. Personal consumption also showed signs of a modest pick-up, despite persisting sluggishness in some areas due to consumers' increased frugality in the face of rising prices. On the other hand, the outlook of the Japanese economy is still uncertain on account of future trends of US policy, continued concerns about a possible slowdown in overseas economies, persistent instability in financial markets, such as with exchange rate and stock price fluctuations, and rising domestic prices due to soaring resource and materials prices against the backdrop of the protracted conflict in Ukraine, and other factors.

In these circumstances, the Rohto Group is endeavoring under the slogan "Connect for Well-being" to enable people all over the world to feel energized both mentally and physically, and spend every day filled with laughter and happiness throughout the various stages of their lives. With the aim of further increasing corporate value, we are working to realize the Rohto Group Comprehensive Management Vision 2030.

Consequently, net sales increased significantly to 308,625 million yen (up 14.0% year-on-year). In Japan, sales increased, reflecting product proposals that meet customer needs as well as rising inbound demand. Overseas, sales also increased due to product proposals that meet customer needs, depreciation of the yen and addition of Singaporean Chinese herbal medicine manufacturing and sales company Eu Yan Sang International Ltd. and Austrian pharmaceutical and medical device manufacturing and sales company Mono chem-pharm Produkte GmbH, whose shares were newly acquired by the Company, to the scope of consolidation.

As for profits, as a result of a rising cost of sales ratio as well as increased selling, general and administrative expenses due to a planned increase in research and development expenses, operating income was 38,939 million yen (down 2.8% year-on-year), ordinary income was 40,430 million yen (down 4.7% year-on-year), and profit attributable to owners of parent was 31,006 million yen (up 0.2% year-on-year).

Results by reportable segment are as follows.

(Millions of yen)

		Net sales (Sales to customers)			
		Fiscal year ended Mar. 31, 2024	Fiscal year ended Mar. 31, 2025	Year-on-year change (Amount)	Year-on-year change (%)
Reportable segment	Japan	156,851	164,988	8,137	5.2
	Americas	18,565	20,769	2,203	11.9
	Europe	13,884	19,163	5,279	38.0
	Asia	78,751	100,336	21,585	27.4
	Subtotal	268,053	305,258	37,205	13.9
Others		2,786	3,366	579	20.8
Total		270,840	308,625	37,785	14.0

Japan

Sales to outside customers increased to 164,988 million yen (up 5.2% year-on-year).

Sales were brisk for "Rohto V5" supplements, new lip balm products, "Hadalabo" skincare products, "Gyutto," which is a new hair mask product, "CareCera" skincare products, sunscreens, and high-end eye drops. Among the domestic group companies, Rohto Nitten Co., Ltd. contributed to sales growth.

Segment profit (operating income basis) decreased to 22,453 million yen (down 8.1% year-on-year) due to a rising cost of sales ratio as

well as a planned increase in the selling, general and administrative expenses, including research and development expenses.

Americas

Sales to outside customers increased significantly to 20,769 million yen (up 11.9% year-on-year).

Sales of OTC eye drops were strong in the U.S. and Hydrox Laboratories, which manufactures and sells medical disinfectants and other products, continued to perform strongly. In addition, our consolidated subsidiaries in Brazil, which experienced strong sales for “Hadalabo,” also made a contribution to the increase in sales.

Segment profit (operating income basis) increased significantly to 1,542 million yen (up 27.9% year-on-year) owing to profit improvements at Hydrox Laboratories and the consolidated subsidiaries in Brazil.

Europe

Sales to outside customers increased significantly to 19,163 million yen (up 38.0% year-on-year).

Sales of the mainstay anti-inflammatory analgesic products decreased due to timing discrepancies in shipments to the Middle East. However, Dax Cosmetics, based in Poland, contributed to the increase in sales due to the strong sales of “Perfecta” and “Hadalabo Tokyo,” whose target countries of sale have been expanded. In addition, the Company has been developing the eye drop market since 2021 with “Rohto Dry Aid,” whose sales remained strong. Furthermore, Mono chem-pharm Produkte GmbH has also contributed to sales.

Segment profit (operating income basis) increased to 1,425 million yen (up 2.9% year-on-year) due to an increase in sales of Dax Cosmetics, which offset a decrease in sales of the mainstay anti-inflammatory analgesic products.

Asia

Sales to outside customers increased significantly to 100,336 million yen (up 27.4% year-on-year).

Sales were strong in Vietnam, Indonesia, and other Southeast Asian countries. In addition, Eu Yan Sang International Ltd. contributed to sales. On the other hand, stricter import regulations in Myanmar led to difficulties in the import of raw materials and products, which resulted in a significant decrease in sales. Regarding the performance of particular products, “Hadalabo,” “Selsun” antidandruff shampoo and “Acnes” skincare products are among those that contributed to the increase in sales.

Segment profit (operating income basis) was 12,289 million yen (up 2.2% year-on-year) due to an increase of sales in Vietnam and Indonesia, which offset amortization of goodwill of Eu Yan Sang International Ltd. as well as the decrease in sales in Myanmar.

(2) Overview of Financial Position

Total assets at the end of the current fiscal year were 421,875 million yen, an increase of 75,700 million yen from the end of the previous fiscal year. This was mainly due to an increase of 45,208 million yen in goodwill, an increase of 12,197 million yen in right-of-use assets, net, and an increase of 9,971 million yen in merchandise and finished goods, while cash and deposits decreased by 12,048 million yen. Total liabilities were 150,434 million yen, an increase of 51,295 million yen from the end of the previous fiscal year. The main factors were an increase of 25,370 million yen in convertible-bond-type bonds with share acquisition rights and an increase of 12,627 million yen in long-term borrowings, while accrued expenses decreased by 1,847 million yen.

Net assets totaled 271,440 million yen, an increase of 24,404 million yen from the end of the previous fiscal year. This was mainly due to increases in retained earnings and non-controlling interests of 19,043 million yen and 10,634 million yen, respectively, while there was a decrease of 5,000 million yen due to purchase of treasury shares.

(3) Overview of Cash Flows

(Millions of yen)

Item	Fiscal year ended Mar. 31, 2024	Fiscal year ended Mar. 31, 2025	Year-on-year change (Amount)
Cash and cash equivalents at the beginning of the period	77,691	86,562	8,870
Cash flows from operating activities	34,245	36,917	2,671
Cash flows from investing activities	(16,317)	(89,170)	(72,852)
Cash flows from financing activities	(13,784)	35,319	49,103
Effect of exchange rate changes on cash and cash equivalents	4,703	3,374	(1,328)
Increase (decrease) in cash and cash equivalents	8,847	(13,558)	(22,405)
Increase in cash and cash equivalents resulting from inclusion of subsidiaries in consolidation	23	217	194
Cash and cash equivalents at the end of the period	86,562	73,221	(13,340)

Cash and cash equivalents amounted to 73,221 million yen at the end of the current fiscal year, a decrease of 13,340 million yen from the end of the previous fiscal year.

Operating activities

Net cash provided by operating activities in the current fiscal year amounted to 36,917 million yen, an increase of 2,671 million yen from the previous fiscal year. While income before income taxes amounted to 42,331 million yen and depreciation, which is a factor contributing to a cash flow increase, amounted to 11,620 million yen, there were income taxes paid of 11,237 million yen, a 4,597 million yen increase in inventories and a 3,931 million yen gain on sale of investment securities, which are factors contributing to a cash flow decrease.

Investing activities

Net cash used in investing activities in the current fiscal year amounted to 89,170 million yen, an increase of 72,852 million yen from the previous fiscal year. This was mainly due to payments of 74,479 million yen for the purchase of shares of subsidiaries resulting in change in scope of consolidation and 9,080 million yen for the purchase of property, plant and equipment.

Financing activities

Net cash provided by financing activities amounted to 35,319 million yen in the current fiscal year, compared to 13,784 million yen used in the previous fiscal year. This was mainly due to proceeds from share issuance to non-controlling shareholders of 31,620 million yen and proceeds from issuance of convertible bonds of 25,270 million yen.

(4) Future Outlook

(Millions of yen)

	Net sales	Operating income	Ordinary income	Profit attributable to owners of parent
Fiscal year ending Mar. 31, 2026 (forecast)	334,500	39,000	40,500	31,100
Fiscal year ended Mar. 31, 2025 (results)	308,625	38,939	40,430	31,006
Year-on-year change (%)	8.4	0.2	0.2	0.3

With regard to the economic outlook, the moderate recovery trend of the Japanese economy is expected to continue against the backdrop of wage hikes, expansion of capital investment, and rising inbound demand despite concerns about households' growing frugality due to persisting price increases. On the other hand, the outlook for overseas economies remains uncertain, as the environment for personal consumption is expected to remain challenging due to factors such as the growing uncertainty of trade policies.

In these circumstances, the Rohto Group will adapt to the changes in the business environment, aiming to expand business further and improve earnings, by creating new products that respond appropriately to changing customer needs. The Group is also endeavoring to achieve innovations, including through alliances with a wide range of companies.

In view of this situation, for the fiscal year ending March 31, 2026, the Company projects net sales of 334.5 billion yen, operating income of 39.0 billion yen, ordinary income of 40.5 billion yen, and profit attributable to owners of parent of 31.1 billion yen.

These forecasts are based on an exchange rate of 142 yen to the U.S. dollar and 19 yen to the Chinese yuan.

2. Basic Approach to the Selection of Accounting Standards

The Rohto Group will continue to prepare consolidated financial statements using the generally accepted accounting principles in Japan for the time being to permit comparisons with prior years and with the financial data of other companies.

We will take suitable actions with regard to the application of International Financial Reporting Standards by taking into account associated factors in Japan and other countries.

Consolidated Financial Statements

(1) Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2024	As of March 31, 2025
Assets		
Current assets		
Cash and deposits	89,210	77,161
Notes and accounts receivable - trade	44,744	47,129
Electronically recorded monetary claims - operating	24,779	23,261
Merchandise and finished goods	26,414	36,386
Work in process	3,914	5,059
Raw materials and supplies	16,329	20,135
Other	9,773	9,255
Allowance for doubtful accounts	(408)	(510)
Total current assets	214,759	217,879
Non-current assets		
Property, plant and equipment		
Buildings and structures	67,695	77,292
Accumulated depreciation	(37,824)	(44,003)
Buildings and structures, net	29,871	33,288
Machinery, equipment and vehicles	70,227	79,529
Accumulated depreciation	(57,176)	(63,552)
Machinery, equipment and vehicles, net	13,050	15,976
Tools, furniture and fixtures	20,577	26,436
Accumulated depreciation	(17,232)	(21,799)
Tools, furniture and fixtures, net	3,344	4,636
Land	15,010	16,970
Right-of-use assets	4,303	26,986
Accumulated depreciation	(1,285)	(11,771)
Right-of-use assets, net	3,018	15,215
Construction in progress	4,288	4,344
Other	307	235
Accumulated depreciation	(283)	(215)
Other, net	24	20
Total property, plant and equipment	68,607	90,451
Intangible assets		
Goodwill	2,285	47,494
Other	6,931	8,575
Total intangible assets	9,217	56,069
Investments and other assets		
Investment securities	44,337	46,427
Long-term loans receivable	5,990	6,751
Retirement benefit asset	1,846	2,149
Deferred tax assets	3,869	3,975
Other	4,555	5,555
Allowance for doubtful accounts	(7,008)	(7,484)
Total investments and other assets	53,590	57,375
Total non-current assets	131,415	203,896
Deferred assets		
Bond issuance costs	-	99
Total deferred assets	-	99
Total assets	346,175	421,875

(Millions of yen)

	As of March 31, 2024	As of March 31, 2025
Liabilities		
Current liabilities		
Notes and accounts payable - trade	16,991	19,050
Electronically recorded obligations - operating	4,132	3,006
Short-term borrowings	5,304	7,035
Accrued expenses	21,985	20,138
Income taxes payable	5,071	5,975
Accrued consumption taxes	1,572	988
Provision for bonuses	3,685	4,161
Provision for bonuses for directors (and other officers)	50	65
Refund liabilities	15,163	16,343
Other	13,129	17,843
Total current liabilities	87,087	94,608
Non-current liabilities		
Convertible-bond-type bonds with share acquisition rights	-	25,370
Long-term borrowings	5,190	17,818
Deferred tax liabilities	1,597	2,081
Retirement benefit liability	2,548	1,770
Provision for loss on guarantees	37	3
Other	2,677	8,783
Total non-current liabilities	12,051	55,826
Total liabilities	99,138	150,434
Net assets		
Shareholders' equity		
Share capital	6,504	6,504
Capital surplus	4,516	-
Retained earnings	209,399	228,442
Treasury shares	(4,939)	(9,939)
Total shareholders' equity	215,480	225,007
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	11,276	9,466
Foreign currency translation adjustment	18,594	23,813
Remeasurements of defined benefit plans	591	1,425
Total accumulated other comprehensive income	30,461	34,705
Share acquisition rights	382	382
Non-controlling interests	710	11,345
Total net assets	247,036	271,440
Total liabilities and net assets	346,175	421,875

(2) Consolidated Statements of Income and Comprehensive Income

Consolidated Statements of Income

(Millions of yen)

	For the fiscal year ended March 31, 2024	For the fiscal year ended March 31, 2025
Net sales	270,840	308,625
Cost of sales	113,554	133,686
Gross profit	157,285	174,939
Selling, general and administrative expenses		
Promotion expenses	16,242	18,282
Advertising expenses	37,977	39,224
Salaries and bonuses	19,807	24,773
Provision for bonuses	1,528	1,562
Provision for bonuses for directors (and other officers)	50	50
Retirement benefit expenses	624	590
Depreciation	1,987	4,035
Amortization of goodwill	436	1,523
Research and development expenses	13,390	14,912
Provision of allowance for doubtful accounts	47	8
Other	25,145	31,037
Total selling, general and administrative expenses	117,237	135,999
Operating income	40,048	38,939
Non-operating income		
Interest income	1,523	1,223
Dividend income	486	556
Share of profit of entities accounted for using equity method	-	166
Foreign exchange gains	447	516
Reversal of allowance for doubtful accounts	118	-
Gain on investments in investment partnerships	-	143
Other	972	900
Total non-operating income	3,547	3,507
Non-operating expenses		
Interest expenses	196	949
Share of loss of entities accounted for using equity method	289	-
Loss on investments in investment partnerships	207	-
Provision of allowance for doubtful accounts	-	475
Other	467	590
Total non-operating expenses	1,161	2,016
Ordinary income	42,434	40,430

(Millions of yen)

	For the fiscal year ended March 31, 2024	For the fiscal year ended March 31, 2025
Extraordinary income		
Gain on sale of investment securities	-	3,931
Gain on sale of shares of subsidiaries and associates	-	39
National subsidies	230	181
Total extraordinary income	230	4,151
Extraordinary losses		
Impairment losses	118	51
Loss on tax purpose reduction entry of non-current assets	230	124
Loss on valuation of investment securities	731	2,048
Loss on valuation of shares of subsidiaries and associates	67	26
Total extraordinary losses	1,146	2,251
Income before income taxes	41,518	42,331
Income taxes - current	9,955	11,627
Income taxes - deferred	168	(247)
Total income taxes	10,123	11,379
Net income	31,394	30,951
Profit (loss) attributable to non-controlling interests	457	(54)
Profit attributable to owners of parent	30,936	31,006

Consolidated Statements of Comprehensive Income

(Millions of yen)

	For the fiscal year ended March 31, 2024	For the fiscal year ended March 31, 2025
Net income	31,394	30,951
Other comprehensive income		
Valuation difference on available-for-sale securities	3,376	(1,809)
Foreign currency translation adjustment	8,003	5,034
Remeasurements of defined benefit plans, net of tax	869	834
Share of other comprehensive income of entities accounted for using equity method	4	1
Total other comprehensive income	12,253	4,060
Comprehensive income	43,647	35,012
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	43,075	35,249
Comprehensive income attributable to non-controlling interests	572	(236)

(3) Consolidated Statements of Changes in Equity

For the fiscal year ended March 31, 2024

(Millions of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	6,504	5,292	184,005	(4,938)	190,864
Changes during period					
Dividends of surplus			(5,475)		(5,475)
Profit attributable to owners of parent			30,936		30,936
Purchase of treasury shares				(0)	(0)
Change in scope of consolidation			(68)		(68)
Increase in retained earnings from decrease of entities accounted for by the equity method					-
Transfer from retained earnings to capital surplus					-
Change in ownership interest of parent due to transactions with non-controlling interests		(776)			(776)
Net changes in items other than shareholders' equity					
Total changes during period	-	(776)	25,393	(0)	24,616
Balance at end of period	6,504	4,516	209,399	(4,939)	215,480

	Accumulated other comprehensive income			
	Valuation difference on available-for-sale securities	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income
Balance at beginning of period	7,951	10,649	(277)	18,323
Changes during period				
Dividends of surplus				
Profit attributable to owners of parent				
Purchase of treasury shares				
Change in scope of consolidation				
Increase in retained earnings from decrease of entities accounted for by the equity method				
Transfer from retained earnings to capital surplus				
Change in ownership interest of parent due to transactions with non-controlling interests				
Net changes in items other than shareholders' equity	3,324	7,944	869	12,138
Total changes during period	3,324	7,944	869	12,138
Balance at end of period	11,276	18,594	591	30,461

	Share acquisition rights	Non-controlling interests	Total net assets
Balance at beginning of period	382	5,508	215,078
Changes during period			
Dividends of surplus			(5,475)
Profit attributable to owners of parent			30,936
Purchase of treasury shares			(0)
Change in scope of consolidation			(68)
Increase in retained earnings from decrease of entities accounted for by the equity method			-
Transfer from retained earnings to capital surplus			-
Change in ownership interest of parent due to transactions with non-controlling interests			(776)
Net changes in items other than shareholders' equity	-	(4,797)	7,341
Total changes during period	-	(4,797)	31,957
Balance at end of period	382	710	247,036

For the fiscal year ended March 31, 2025

(Millions of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	6,504	4,516	209,399	(4,939)	215,480
Changes during period					
Dividends of surplus			(7,072)		(7,072)
Profit attributable to owners of parent			31,006		31,006
Purchase of treasury shares				(5,000)	(5,000)
Change in scope of consolidation			(255)		(255)
Increase in retained earnings from decrease of entities accounted for by the equity method			289		289
Transfer from retained earnings to capital surplus		4,924	(4,924)		-
Change in ownership interest of parent due to transactions with non-controlling interests		(9,440)			(9,440)
Net changes in items other than shareholders' equity					
Total changes during period	-	(4,516)	19,043	(5,000)	9,526
Balance at end of period	6,504	-	228,442	(9,939)	225,007

	Accumulated other comprehensive income			
	Valuation difference on available-for-sale securities	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income
Balance at beginning of period	11,276	18,594	591	30,461
Changes during period				
Dividends of surplus				
Profit attributable to owners of parent				
Purchase of treasury shares				
Change in scope of consolidation				
Increase in retained earnings from decrease of entities accounted for by the equity method				
Transfer from retained earnings to capital surplus				
Change in ownership interest of parent due to transactions with non-controlling interests				
Net changes in items other than shareholders' equity	(1,810)	5,219	834	4,243
Total changes during period	(1,810)	5,219	834	4,243
Balance at end of period	9,466	23,813	1,425	34,705

	Share acquisition rights	Non-controlling interests	Total net assets
Balance at beginning of period	382	710	247,036
Changes during period			
Dividends of surplus			(7,072)
Profit attributable to owners of parent			31,006
Purchase of treasury shares			(5,000)
Change in scope of consolidation			(255)
Increase in retained earnings from decrease of entities accounted for by the equity method			289
Transfer from retained earnings to capital surplus			-
Change in ownership interest of parent due to transactions with non-controlling interests			(9,440)
Net changes in items other than shareholders' equity	-	10,634	14,877
Total changes during period	-	10,634	24,404
Balance at end of period	382	11,345	271,440

(4) Consolidated Statements of Cash Flows

(Millions of yen)

	For the fiscal year ended March 31, 2024	For the fiscal year ended March 31, 2025
Cash flows from operating activities		
Income before income taxes	41,518	42,331
Depreciation	8,251	11,620
Impairment losses	118	51
Amortization of goodwill	436	1,523
Increase (decrease) in allowance for doubtful accounts	17	64
Increase (decrease) in provision for bonuses	146	(260)
Increase (decrease) in retirement benefit liability	97	(27)
Increase (decrease) in provision for loss on guarantees	-	(23)
Bad debt expense	-	475
Reversal of allowance for doubtful accounts	(118)	-
Loss on tax purpose reduction entry of non-current assets	230	124
National subsidies	(230)	(181)
Loss (gain) on sale of investment securities	(3)	(3,931)
Loss (gain) on valuation of investment securities	731	2,048
Loss on valuation of shares of subsidiaries and associates	67	26
Loss (gain) on sale of shares of subsidiaries and associates	-	(39)
Interest and dividend income	(2,009)	(1,780)
Interest expenses	196	949
Share of loss (profit) of entities accounted for using equity method	289	(166)
Decrease (increase) in trade receivables	(6,787)	1,950
Decrease (increase) in inventories	(4,029)	(4,597)
Increase (decrease) in trade payables	1,679	(1,288)
Other, net	2,051	(1,851)
Subtotal	42,653	47,018
Interest and dividends received	1,762	2,005
Interest paid	(200)	(888)
Income taxes paid	(10,041)	(11,237)
Income taxes refund	71	18
Net cash provided by (used in) operating activities	34,245	36,917

(Millions of yen)

	For the fiscal year ended March 31, 2024	For the fiscal year ended March 31, 2025
Cash flows from investing activities		
Payments into time deposits	(1,549)	(2,705)
Proceeds from withdrawal of time deposits	1,430	1,517
Purchase of property, plant and equipment	(7,979)	(9,080)
Proceeds from sale of property, plant and equipment	272	26
Purchase of intangible assets	(933)	(1,481)
Purchase of investment securities	(7,531)	(6,832)
Proceeds from sale and redemption of investment securities	274	4,457
Purchase of shares of subsidiaries resulting in change in scope of consolidation	-	(74,479)
Subsidies received	230	181
Long-term loan advances	(619)	(758)
Proceeds from collection of long-term loans receivable	88	2
Other, net	(0)	(18)
Net cash provided by (used in) investing activities	(16,317)	(89,170)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	656	(2,310)
Proceeds from long-term borrowings	1,605	14,908
Repayments of long-term borrowings	(3,484)	(5,961)
Proceeds from issuance of convertible bonds	-	25,270
Purchase of treasury shares	(0)	(5,000)
Dividends paid	(5,475)	(7,072)
Proceeds from share issuance to non-controlling shareholders	-	31,620
Dividends paid to non-controlling interests	(1)	(1)
Purchase of shares of subsidiaries not resulting in change in scope of consolidation	(6,144)	(13,505)
Other, net	(938)	(2,626)
Net cash provided by (used in) financing activities	(13,784)	35,319
Effect of exchange rate change on cash and cash equivalents	4,703	3,374
Net increase (decrease) in cash and cash equivalents	8,847	(13,558)
Cash and cash equivalents at beginning of period	77,691	86,562
Increase in cash and cash equivalents resulting from inclusion of subsidiaries in consolidation	23	217
Cash and cash equivalents at end of period	86,562	73,221

(5) Notes to Consolidated Financial Statements**Going Concern Assumption**

No reportable information.

Changes in Accounting Policies

Application of “Accounting Standard for Current Income Taxes,” etc.

The Company has applied the “Accounting Standard for Current Income Taxes” (ASBJ Statement No. 27, October 28, 2022; hereafter referred to as the “Revised Accounting Standard of 2022”) and other relevant standards from the beginning of the current fiscal year.

With regard to revisions to categories for recording current income taxes (taxation on other comprehensive income), the Company complies with the transitional treatment stipulated in the proviso of paragraph 20-3 of the Revised Accounting Standard of 2022 and the transitional treatment stipulated in the proviso of paragraph 65-2 (2) of the “Guidance on Accounting Standard for Tax Effect Accounting” (ASBJ Guidance No. 28, October 28, 2022; hereafter referred to as the “Revised Guidance of 2022”). These changes in the accounting policy do not affect the consolidated financial statements.

In addition, since the beginning of the current fiscal year, the Revised Guidance of 2022 has also been applied to the amendments related to the review of the treatment in consolidated financial statements when profits or losses arising from the sale of subsidiary shares, etc. between consolidated companies are deferred for tax purposes. These changes in the accounting policy have been applied retroactively, and the consolidated financial statements for the previous fiscal year reflect the changes that have been applied retroactively. These changes in the accounting policy do not affect the consolidated financial statements for the previous fiscal year.

Application of the “Practical Solution on the Accounting for and Disclosure of Current Taxes Related to the Global Minimum Tax Rules”
The Company has applied the “Practical Solution on the Accounting for and Disclosure of Current Taxes Related to the Global Minimum Tax Rules” (ASBJ Practical Solution No. 46, March 22, 2024) from the beginning of the current fiscal year.

In October 2021, member countries participating in the OECD/G20 “Inclusive Framework on Base Erosion and Profit Shifting” agreed on global minimum taxation. In response, in Japan the “Act Partially Amending the Income Tax Act and Other Relevant Acts” (Act No. 3 of 2023) enacted on March 28, 2023, stipulates the treatment of the Income Inclusion Rule (IIR) among the internationally agreed global minimum tax rules, which is to be applied to fiscal years beginning on or after April 1, 2024.

The objective of global minimum taxation is to impose corporation taxes at a minimum tax rate of 15% on the country-by-country profit of multinational enterprises, etc. that meet certain requirements. It is a new tax system under which the company that generates net income (profit) that is the source of the said taxation and the company that is liable to pay the tax are different.

The “Practical Solution on the Accounting for and Disclosure of Current Taxes Related to the Global Minimum Tax Rules” presents the accounting treatment and disclosure of corporation taxes and local corporation taxes related to the global minimum tax rules. This change in accounting policy has no impact on the consolidated financial statements.

Changes in Presentation

(Consolidated balance sheets)

“Retirement benefit asset,” which was included in “Other” under “Investments and other assets” in the previous fiscal year, is separately presented in the current fiscal year due to increased materiality of the amount. To reflect this change in presentation, the consolidated financial statements for the previous fiscal year have been reclassified.

As a result, 6,402 million yen presented as “Other” under “Investments and other assets” in the consolidated balance sheets for the previous fiscal year has been reclassified as “retirement benefit asset” of 1,846 million yen and “Other” of 4,555 million yen.

“Right-of-use assets, net,” which was included in “Other, net” under “Property, plant and equipment” in the previous fiscal year, is separately presented in the current fiscal year due to increased materiality of the amount. To reflect this change in presentation, the consolidated financial statements for the previous fiscal year have been reclassified.

As a result, 3,042 million yen presented as “Other, net” under “Property, plant and equipment” in the consolidated balance sheets for the previous fiscal year has been reclassified as “right-of-use assets, net” of 3,018 million yen and “Other, net” of 24 million yen.

(Consolidated statements of cash flows)

“Loss (gain) on sale of investment securities,” which was included in “Other” under “Cash flows from operating activities” in the previous fiscal year, is separately presented in the current fiscal year due to increased materiality of the amount. To reflect this change in presentation, the consolidated financial statements for the previous fiscal year have been reclassified.

As a result, 2,048 million yen presented as “Other” under “Cash flows from operating activities” in the consolidated statements of cash flows for the previous fiscal year has been reclassified as “loss (gain) on sale of investment securities” of (3) million yen and “Other” of 2,051 million yen.

“Purchase of treasury shares,” which was included in “Other” under “Cash flows from financing activities” in the previous fiscal year, is separately presented in the current fiscal year due to increased materiality of the amount. To reflect this change in presentation, the consolidated financial statements for the previous fiscal year have been reclassified.

As a result, (939) million yen presented as “Other” under “Cash flows from financing activities” in the consolidated statements of cash flows for the previous fiscal year has been reclassified as “purchase of treasury shares” of (0) million yen and “Other” of (938) million yen.

Changes in the Scope of Consolidation and the Scope of Application of Equity Method

Significant changes in the scope of consolidation

Starting from the first quarter of the current fiscal year, Soar R2M Pte. Ltd., which the Company has newly established, and Eu Yan Sang International Ltd. and 36 other companies, whose shares it has newly acquired, have been included in the scope of consolidation.

Starting from the second quarter of the current fiscal year, Rohto-Mentholatum Austria GmbH, which the Company has newly established, and Mono chem-pharm Produkte GmbH and 3 other companies, whose shares it has newly acquired, have been included in the scope of consolidation. Additionally, Mentholatum Shanghai Cosmetics Company Ltd. has been excluded from the scope of consolidation due to liquidation.

Starting from the fourth quarter of the current fiscal year, ROHTO-Mentholatum (Cambodia) Co., Ltd, which was a nonconsolidated subsidiary, have been included in the scope of consolidation due to the increased materiality.

Significant changes in the scope of application of equity method

Starting from the first quarter of the current fiscal year, CAFÉ COMPANY Inc. has been excluded from the scope of application of equity method due to the sale of its shares by the Company.

Business Combination, etc.

Business combination through acquisition

(Making Eu Yan Sang International Ltd. a consolidated subsidiary through acquisition of shares)

1. Outline of the business combination

(1) Name of the acquired company and description of its business

Name of the acquired company: Eu Yan Sang International Ltd.

Description of business: Manufacture and sale of Chinese herbal medicines, food, etc.

(2) Main reasons for the business combination

We are developing business based on our purpose, that is, to lead all individuals and society surrounding us to “well-being” by delivering “health” to people around the world through our products and services. Under the Business Domain Vision 2030, we aim to further expand and strengthen our core businesses of OTC drugs, skincare, and food. By product and service sales, the skincare business currently accounts for 65% of net sales (for the fiscal year ended March 31, 2024). In order to offer solutions for all aspects of health, however, it is essential to further strengthen OTC drugs and food businesses, and further growth is expected in the Asian region, which accounts for approximately 30% of sales by region (for the fiscal year ended March 31, 2024). By combining the strong competitiveness of Eu Yan Sang International Ltd.’s products and brand in Asia with our R&D and sales capabilities, we aim to create an innovative business and realize an unprecedented health business.

(3) Date of business combination

June 3, 2024 (Deemed acquisition date: June 30, 2024)

(4) Legal form of business combination

Share acquisition in cash

(5) Name of company after combination

No change

(6) Percentage of voting rights acquired

85.91%

(7) Primary reason for determining the acquiring company

Acquisition of shares in cash by the Group

2. The period of financial results of the acquired company included in the consolidated statement of income for the current fiscal year

Since June 30, 2024 is the deemed acquisition date, and the difference from the consolidated closing date does not exceed three months, the financial results of the acquired company from July 1, 2024 to December 31, 2024 are included in the consolidated statement of income for the current fiscal year.

3. Acquisition cost of the acquired company and breakdown by type of consideration

The acquisition price was determined by using outside experts to assess the value of the acquired company’s business based on its business plan.

Consideration for acquisition	Cash	694.5 million Singapore dollars (80,840 million yen)
Acquisition cost		694.5 million Singapore dollars (80,840 million yen)

4. Description and amount of major acquisition-related costs

Advisory fees, etc.	209 million yen
---------------------	-----------------

5. Amount and cause of goodwill, amortization method, and amortization period

(1) Resulting amount of goodwill

44,792 million yen

The amount above is provisionally calculated since the allocation of the acquisition cost has not been complete at the end of the current fiscal year.

(2) Cause

The goodwill is based on the excess earning power expected as a result of future business expansion.

(3) Method and period of amortization

Straight-line amortization over 20 years

6. Amounts of assets acquired and liabilities assumed on the date of business combination and major items thereof

Current assets	16,360 million yen
Non-current assets	16,614 million yen
Total assets	32,975 million yen
Current liabilities	10,833 million yen
Non-current liabilities	5,656 million yen
Total liabilities	16,490 million yen

7. Estimated amount of and calculation method for the effect of the business combination on the consolidated financial statement of income for the current fiscal year if the business combination had been completed at the beginning of the current fiscal year

Net sales	18,502 million yen
Operating income	1,702 million yen
Ordinary income (loss)	(846) million yen

(Method of calculation of the estimated amount)

The difference between the net sales and profit/loss information calculated as if the business combination had been completed at the beginning of the current fiscal year and the net sales and profit/loss information of the acquired company in the consolidated statement of income is the estimated amount of the effect. The notes are unaudited.

(Making Mono chem-pharm Produkte GmbH a consolidated subsidiary through acquisition of shares)

1. Outline of the business combination

(1) Name of the acquired company and description of its business

Name of the acquired company:	Mono chem-pharm Produkte GmbH
Description of business:	Manufacture, wholesale, sale and export of pharmaceuticals and medical devices

(2) Main reasons for the business combination

We are developing business based on our purpose, that is, to lead all individuals and society surrounding us to “well-being” by delivering “health” to people around the world through our products and services. Under the Rohto Group Comprehensive Management Vision 2030, we aim to further expand and strengthen our core businesses of OTC drugs, skincare, and food. Europe accounts for 5.1% of our sales by region (for the fiscal year ended March 31, 2024). It is essential to further strengthen OTC drugs and medical devices in order to provide more diverse product solutions to the European market, which has room for expansion. Mono chem-pharm Produkte GmbH, which is capable of producing high-quality products that comply with the latest European pharmaceuticals regulations and medical device regulations, is expected to grow further in the future.

(3) Date of business combination

August 23, 2024 (Deemed acquisition date: June 30, 2024)

(4) Legal form of business combination

Subscription to third-party allotment of new shares and share acquisition in cash

(5) Name of company after combination

No change

(6) Percentage of voting rights acquired

51.0%

(7) Primary reason for determining the acquiring company

Subscription to third-party allotment of new shares and acquisition of shares in cash by the Group

2. The period of financial results of the acquired company included in the consolidated statement of income for the current fiscal year

Since June 30, 2024 is the deemed acquisition date, and the difference from the consolidated closing date does not exceed three months, the financial results of the acquired company from July 1, 2024 to December 31, 2024 are included in the consolidated statement of income for the current fiscal year.

3. Acquisition cost of the acquired company and breakdown by type of consideration

The acquisition price was determined by assessing the value of the acquired company's business based on its business plan.

Consideration for acquisition	Cash	30 million euro (4,880 million yen)
Acquisition cost		30 million euro (4,880 million yen)

4. Description and amount of major acquisition-related costs

Advisory fees, etc.	71 million yen
---------------------	----------------

5. Amount and cause of goodwill, amortization method, and amortization period

(1) Resulting amount of goodwill

1,715 million yen

The amount above is provisionally calculated since the allocation of the acquisition cost has not been complete at the end of the current fiscal year.

(2) Cause

The goodwill is based on the excess earning power expected as a result of future business expansion.

(3) Method and period of amortization

Straight-line amortization over 15 years

6. Amounts of assets acquired and liabilities assumed on the date of business combination and major items thereof

Current assets	7,466 million yen
Non-current assets	4,054 million yen
Total assets	11,521 million yen
Current liabilities	3,914 million yen
Non-current liabilities	1,421 million yen
Total liabilities	5,335 million yen

7. Estimated amount of and calculation method for the effect of the business combination on the consolidated financial statement of income for the current fiscal year if the business combination had been completed at the beginning of the current fiscal year

Net sales	2,492 million yen
Operating income	2 million yen
Ordinary income (loss)	(87) million yen

(Method of calculation of the estimated amount)

The difference between the net sales and profit/loss information calculated as if the business combination had been completed at the beginning of the current fiscal year and the net sales and profit/loss information of the acquired company in the consolidated statement of income is the estimated amount of the effect. The notes are unaudited.

Common control transaction, etc.

(Third-party allotment of new shares by a consolidated subsidiary (Soar R2M Pte. Ltd.))

1. Outline of the transaction

(1) Name of the constituent company and description of its business

Name of the constituent company:	Soar R2M Pte. Ltd.
----------------------------------	--------------------

Description of business:	Holding company
--------------------------	-----------------

(2) Date of business combination

May 31, 2024, August 2, 2024

(3) Legal form of business combination

Third-party allotment of new shares to third parties other than the Company and its subsidiaries

(4) Name of company after combination

No change

(5) Other matters concerning the outline of the transaction

In order to acquire shares of Singaporean Chinese herbal medicine manufacturing and sales company Eu Yan Sang International Ltd. and make it a subsidiary, Soar R2M Pte. Ltd. issued new shares through third-party allotment to Mitsui & Co. and the founding family. As a result, the Company's ownership ratio became 66.67% on May 31, 2024 and 60.00% on August 2, 2024.

2. Outline of the implemented accounting processes

In accordance with the "Accounting Standard for Business Combinations" (ASBJ Statement No. 21, January 16, 2019) and

the “Implementation Guidance on Accounting Standard for Business Combinations and Accounting Standard for Business Divestitures” (ASBJ Guidance No. 10, January 16, 2019), the transaction was treated as a transaction with a non-controlling shareholder among common control transactions, etc.

3. Changes in the Company’s interest in transactions with non-controlling shareholders

(1) Major causes of changes in capital surplus

Change in equity due to third-party allotment of new shares to third parties other than the Company and its subsidiaries

(2) Amount of capital surplus decreased due to transactions with non-controlling shareholders

582 million yen

(Acquisition of additional shares of a subsidiary (Eu Yan Sang International Ltd.))

1. Outline of the transaction

(1) Name of the constituent company and description of its business

Name of the constituent company: Eu Yan Sang International Ltd.

Description of business: Manufacture and sale of traditional Chinese medicines, food, etc.

(2) Date of business combination

June 20, 26, July 2, 8, 10, 16, 24, 30, and August 29, 2024

(3) Legal form of business combination

Acquisition of shares from non-controlling shareholders

(4) Name of company after combination

No change

(5) Other matters concerning the outline of the transaction

The Company’s subsidiary Soar R2M Pte. Ltd. acquired additional shares of Eu Yan Sang International Ltd. through a mandatory tender offer in stages beginning on June 10, 2024. Subsequently, Soar R2M Pte. Ltd. exercised its power under Section 215 (1) of the Companies Act of Singapore to compulsorily acquire the shares held by shareholders dissenting from the tender offer at the tender offer price, thereby making Eu Yan Sang International Ltd. its wholly owned subsidiary as of August 29, 2024.

2. Outline of the implemented accounting processes

In accordance with the “Accounting Standard for Business Combinations” (ASBJ Statement No. 21, January 16, 2019) and the “Implementation Guidance on Accounting Standard for Business Combinations and Accounting Standard for Business Divestitures” (ASBJ Guidance No. 10, January 16, 2019), the transaction was treated as a transaction with a non-controlling shareholder among common control transactions, etc.

3. Matters to be reported in the case of acquisition of additional shares of a subsidiary

Acquisition cost of the acquired company and breakdown by type of consideration

Consideration for acquisition	Cash	113.8 million Singapore dollars (13,505 million yen)
Acquisition cost		113.8 million Singapore dollars (13,505 million yen)

4. Changes in the Company’s interest in transactions with non-controlling shareholders

(1) Major causes of changes in capital surplus

Acquisition of additional shares of a subsidiary

(2) Amount of capital surplus decreased due to transactions with non-controlling shareholders

8,763 million yen

Segment and Other Information

Segment Information

1. Overview of reportable segments

Segments used for financial reporting are the Company's constituent units for which separate financial information is available and for which the Board of Directors performs periodic studies for the purposes of determining the allocation of resources and evaluating performance.

The Company undertakes manufacture and sales activities mainly in the health and beauty care categories. Within Japan, these operations are mainly handled by the Company. Overseas, operations are mainly handled by The Mentholatum Company, Inc. in Americas, The Mentholatum Company Ltd. (UK) in Europe, and The Mentholatum (Asia Pacific) Ltd., Mentholatum (China) Pharmaceutical Co., Ltd. and Eu Yan Sang International Ltd. in Asia, together with overseas affiliates.

These affiliates each operate as autonomous business units, formulating comprehensive strategies in each region and developing business activities for the products and services they undertake.

Accordingly, the Company comprises the four geographical reportable segments of Japan, Americas, Europe, and Asia based on our manufacturing and sales structure. In each segment, we manufacture and sell eye care (including eye drops and eyewash preparations), skincare (including dermal medicines, lip balm, sunscreens, and functional cosmetics, etc.), internal medicines (including gastrointestinal medicines, traditional Chinese herbal medicines and supplements), and other products and services, such as in-vitro test kits.

2. Calculation methods for net sales, profits/losses, assets, liabilities, and other items for each reportable segment

The accounting treatment methods for reportable segments are generally the same as those listed in "Significant Accounting Policies in the Preparation of Consolidated Financial Statements" presented in the Group's annual securities report (*Yuka Shoken Hokokusho*).

Profits for reportable segments are generally operating income figures. Inter-segment sales and transfers are determined based on market prices.

3. Information related to net sales, profit/loss, assets, liabilities, and other items for each reportable segment

Prior Fiscal Year (Apr. 1, 2023 – Mar. 31, 2024)

(Millions of yen)

	Reportable segment (Note 1)					Others (Note 2)	Total	Adjustment (Note 3)	Reported in consolidated statements of income (Note 4)
	Japan	Americas	Europe	Asia	Subtotal				
Net sales									
Revenue From Contracts with Customers	156,851	18,565	13,884	78,751	268,053	2,786	270,840	—	270,840
(1) Sales to customers	156,851	18,565	13,884	78,751	268,053	2,786	270,840	—	270,840
(2) Inter-segment sales and transfers	3,317	1,508	130	4,356	9,313	43	9,357	(9,357)	—
Total	160,168	20,074	14,015	83,108	277,367	2,830	280,197	(9,357)	270,840
Segment profit	24,437	1,205	1,385	12,028	39,057	240	39,298	750	40,048
Segment assets	231,000	27,860	13,908	102,107	374,876	2,347	377,224	(31,049)	346,175
Segment liabilities	67,529	3,392	3,546	26,673	101,142	398	101,540	(2,401)	99,138
Other items									
Depreciation	6,091	552	234	1,337	8,215	36	8,251	—	8,251
Amortization of goodwill	401	27	—	7	436	—	436	—	436
Increase in property, plant and equipment and intangible fixed assets	7,153	489	421	1,847	9,911	189	10,100	—	10,100

Notes: 1. "Americas" includes the business activities of overseas entities in the U.S. and Brazil, and others; "Europe" those in the U.K, Poland and South Africa, and others; and "Asia" those in China, Taiwan, Vietnam, and others.

2. "Others" is the business that is excluded from reportable segments, and includes the business activities of entities in Australia.

3. (1) "Adjustment" to segment profit of 750 million yen indicates elimination for intersegment transactions.

(2) "Adjustment" to segment assets of (31,049) million yen and liabilities of (2,401) million yen indicate an elimination for intersegment transactions.

4. Segment profit is adjusted with operating income reported in the quarterly consolidated statement of income.

Current Fiscal Year (Apr. 1, 2024– Mar. 31, 2025)

(Millions of yen)

	Reportable segment (Note 1)					Others (Note 2)	Total	Adjustment (Note 3)	Reported in consolidated statements of income (Note 4)
	Japan	Americas	Europe	Asia	Subtotal				
Net sales									
Revenue From Contracts with Customers	164,988	20,769	19,163	100,336	305,258	3,366	308,625	—	308,625
(1) Sales to customers	164,988	20,769	19,163	100,336	305,258	3,366	308,625	—	308,625
(2) Inter-segment sales and transfers	3,864	1,824	170	5,498	11,357	85	11,442	(11,442)	—
Total	168,852	22,593	19,334	105,835	316,616	3,451	320,068	(11,442)	308,625
Segment profit	22,453	1,542	1,425	12,289	37,710	354	38,064	874	38,939
Segment assets	255,255	30,486	26,168	159,877	471,786	2,489	474,276	(52,400)	421,875
Segment liabilities	84,458	3,504	6,311	58,767	153,041	464	153,505	(3,070)	150,434
Other items									
Depreciation	6,659	682	437	3,800	11,580	40	11,620	—	11,620
Amortization of goodwill	325	27	56	1,113	1,523	—	1,523	—	1,523
Increase in property, plant and equipment and intangible fixed assets	8,479	1,091	1,143	4,083	14,798	272	15,070	—	15,070

Notes: 1. "Americas" includes the business activities of overseas entities in the U.S. and Brazil, and others; "Europe" those in the U.K., Poland and South Africa, and others; and "Asia" those in China, Singapore, Malaysia, Vietnam, and others.

2. "Others" is the business that is excluded from reportable segments, and includes the business activities of entities in Australia.

3. (1) "Adjustment" to segment profit of 874 million yen indicates elimination for intersegment transactions.

(2) "Adjustment" to segment assets of (52,400) million yen and liabilities of (3,070) million yen indicate an elimination for intersegment transactions.

4. Segment profit is adjusted with operating income reported in the quarterly consolidated statement of income.

Related information

Prior Fiscal Year (Apr. 1, 2023– Mar. 31, 2024)

Products and services information

(Millions of yen)

	Eye care products	Skincare products	Internal medicines	Others	Total
Sales to customers	53,402	176,816	30,898	9,722	270,840

Current Fiscal Year (Apr. 1, 2024 – Mar. 31, 2025)

Products and services information

(Millions of yen)

	Eye care products	Skincare products	Internal medicines	Others	Total
Sales to customers	55,757	190,486	49,355	13,026	308,625

Impairment loss on fixed assets for each reportable segment

Prior Fiscal Year (Apr. 1, 2023 – Mar. 31, 2024)

(Millions of yen)

	Reportable segment					Others	Adjustment	Total
	Japan	Americas	Europe	Asia	Subtotal			
Impairment losses on fixed assets	118	-	-	-	118	-	-	118

Current Fiscal Year (Apr. 1, 2024 – Mar. 31, 2025)

(Millions of yen)

	Reportable segment					Others	Adjustment	Total
	Japan	Americas	Europe	Asia	Subtotal			
Impairment losses on fixed assets	16	-	-	35	51	-	-	51

Per-share Information

(Yen)

	Prior Fiscal Year (Apr. 1, 2023 – Mar. 31, 2024)	Current Fiscal Year (Apr. 1, 2024 – Mar. 31, 2025)
Net assets per share	1,078.04	1,149.35
Net income per share	135.61	136.11
Diluted net income per share	135.21	135.44

Notes: 1. Basis for calculation of basic net income per share and diluted net income per share are as follows.

(Millions of yen)

Item	Prior Fiscal Year (Apr. 1, 2023 – Mar. 31, 2024)	Current Fiscal Year (Apr. 1, 2024 – Mar. 31, 2025)
Net income per share		
Profit attributable to owners of parent	30,936	31,006
Amount not available to common stock shareholders	—	
Profit attributable to owners of parent applicable to common stock	30,936	31,006
Average number of common stock shares outstanding during the period (thousand shares)	228,138	227,804
Diluted net income per share		
Adjusted to profit attributable to owners of parent (Note)	—	(3)
Increase in the number of common stock shares (thousand shares)	660	1,095
[of which subscription rights to shares (thousand shares)]	(660)	(660)
[of which convertible-bond-type bonds with share acquisition rights (thousand shares)]	(—)	(435)
Summary of dilutive shares not included in the calculation of “diluted net income per share” since there was no dilutive effect.	— — —	

Note: Amortization during the period (net of tax) pertaining to the difference due to the issuance of bonds at a price higher than the face value of the bonds.

Notes: 2. Basis for calculation of net assets per share is as follows.

(Millions of yen)

Item	Prior Fiscal Year (Apr. 1, 2023 – Mar. 31, 2024)	Current Fiscal Year (Apr. 1, 2024 – Mar. 31, 2025)
Total net assets on the balance sheets	247,036	271,440
Deduction from total net assets	1,093	11,728
[of which subscription rights to shares]	(382)	(382)
[of which non-controlling interests]	(710)	(11,345)
Net assets applicable to common stock	245,942	259,712
Number of common stock shares used in calculation of net assets per share (thousand shares)	228,138	225,964

Material Subsequent Events

No reportable information.